Ars Technica1 min read
The FDA wants to pull its approval of a drug. It’s not so easy.
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
By Sara Talpos, Undark MagazineArs Technica

Read the full story
Originally published by Ars Technica on Oct 31, 2026.
Comments
Sign in to join the discussion.